Temazepam (Restoril) is commonly used for the management of insomnia, applied across domains where patients experience symptoms that interfere with daily functioning. This medication is relevant in conditions characterized by periods of heightened symptoms related to sleep disruption.

The medication is used for managing symptom clusters that manifest as both difficulty falling asleep (sleep-onset insufficiency) and frequent awakenings or inability to remain asleep (sleep maintenance fragmentation). This symptomatic assistance is relevant in contexts involving heightened systemic burden, such as situations where sleep stability is temporarily affected by acute stress or major life changes.

“The support provided helps ease the overall symptom burden of sleep deprivation and contributes to a more continuous rest period.”

The use of this medication provides support that helps ease the overall symptom burden of insomnia. By assisting in managing the time it takes to fall asleep and supporting the reduction of nocturnal awakenings, the medication contributes to improved comfort by facilitating a more continuous and restorative night's rest. The support provided helps maintain a sense of stability when symptoms are more noticeable, assisting with functional stability during periods of recovery from sleeplessness.

Quick Fact: Relief for Sleep Onset
This medication is applied to address the specific symptom of prolonged time required to fall asleep (sleep latency), assisting in the initiation of sleep.

Regulatory References

1. NIH MedlinePlus overview

Eligibility for Restoril (Temazepam) Use

Official regulatory documents define strict population eligibility rules for Restoril, which is approved for the short-term treatment of insomnia in adults.

Population Group	Regulatory Status
Pediatric Patients (Under 18)	Use Not Recommended. Safety and efficacy have not been established in this age group.
Older Adults (Geriatric)	Use is permitted, but the lowest effective dose is recommended due to increased sensitivity and risk of adverse effects.

---

Populations and Conditions Contraindicated for Use

Restoril is formally contraindicated (must not be used) in patients with the following conditions, as stated in regulatory labeling:

• Pregnancy: Contraindicated in women who are or may become pregnant due to the risk of fetal harm.
• Known Hypersensitivity: Patients with an allergy to temazepam, its components, or other benzodiazepines.
• Severe Respiratory Insufficiency: Including conditions like sleep apnoea syndrome, due to the risk of respiratory depression.
• Severe Hepatic Insufficiency: Severe liver disease is contraindicated due to the risk of precipitating encephalopathy.
• Myasthenia Gravis.

---

Conditional Use and Restrictions

• Lactation: Use is not recommended by some regulators, and caution is advised if the medicine is used while breastfeeding.
• Chronic Pulmonary Insufficiency: Use with caution, and a lower dose is often required.
• History of Substance Abuse: Use with extreme caution is required due to the risk of abuse and dependence.
• Depression: Should not be used alone to treat depression or anxiety associated with depression.

Interactions with other medicines and products

Interaction scope

• Medicinal product categories with documented interactions: Opioids, alcohol, and general Central Nervous System (CNS) depressants, including sedatives, anxiolytics, hypnotics, antipsychotics, narcotic analgesics, antiepileptic agents, anesthetics, and certain antihistamines. Xanthines, specifically theophylline and aminophylline, are also noted.
• Specific interacting medicines (if explicitly listed): Alcohol (Ethanol), Theophylline, and Aminophylline are directly named in regulatory documents.
• Mechanistic basis of interactions (only if stated in label): Pharmacodynamic (PD) synergism resulting in an additive effect is the basis for interactions with CNS depressants and alcohol. Conversely, the administration of xanthines may reduce the intended sedative effects.
• Population-specific interaction notes (if applicable): The possibility of interaction with other psychoactive drugs or alcohol is enhanced in cases where the product's half-lives are long, leading to drug accumulation and potential impairment during waking hours.

Interaction-related restrictions and classifications

• Opioid Restriction: The co-administration of this product with opioid-containing medicines carries the FDA's most serious safety classification (Boxed Warning) due to the risk of profound sedation and respiratory depression. Prescribing this combination is officially reserved for patients for whom alternative treatment is inadequate.
• Procedural Constraints: If co-prescribing with opioids is deemed necessary, official regulatory guidelines mandate the use of the lowest effective dosages and minimum durations required.
• CNS Depressants and Alcohol: All official regulatory documents state that the consumption of alcohol and the concurrent use of other CNS depressants will add to the product's central depressive effects.

How Restoril (Temazepam) Works

Temazepam, the active pharmaceutical ingredient in Restoril, acts as a GABA-A receptor positive allosteric modulator (PAM). Its primary biological target is the inhibitory GABAA receptor complex, a ligand-gated ion channel expressed widely throughout the central nervous system (CNS).

Temazepam binds to a distinct, non-GABA site located between the alpha and gamma subunits of this receptor. This binding induces a conformational change that increases the receptor's affinity for the native neurotransmitter, GABA. Consequently, when GABA binds, the frequency of channel opening is enhanced, permitting a greater influx of chloride ions ( Cl^-) into the neuron.

This increased chloride conductance drives neuronal hyperpolarization, which stabilizes the membrane potential and significantly inhibits the overall transmission of nerve impulses. The widespread potentiation of GABA-mediated inhibitory neurotransmission across the CNS results in a generalized central depressant effect on overall neuronal excitability.

How to Use Restoril

Restoril (temazepam) is administered as an oral capsule and its usage is defined by specific administration patterns. The core principle of administration is for the short-term management of insomnia, which is generally defined as a course of 7 to 10 consecutive days. Treatment should typically not exceed a total duration of four weeks, including the necessary tapering period.

---

Official Dosing and Timing

Feature	Official Instruction
Route of Administration	Oral
Standard Adult Dose	15 mg once daily at bedtime
Approved Dose Range	7.5 mg to 30 mg once daily
Frequency	Once daily (single dose)

The medication must be taken as a single dose immediately before going to bed. This time-critical instruction requires the patient to ensure they have the ability to get a full night’s sleep of 7 to 8 hours following administration.

Administration Rules for Specific Populations

For older adults or debilitated patients, therapy is initiated with the lower dose of 7.5 mg taken at bedtime. This adjustment is a required starting point to determine individual response.

Handling Missed Timing

If the dose is missed and the patient is unable to get a full 7 to 8 hours of sleep, the official instruction is to skip the missed dose and wait until the following night. The dose must not be doubled, and it should never be taken later in the night or during the day. Following any period of extended therapy, the medicine must be discontinued via a gradual taper rather than an abrupt cessation.

Research Evidence / Overview of Studies for Restoril

This overview summarizes the structure and nature of the clinical research conducted on temazepam, focusing on what types of studies have been performed, which outcomes they measured, and where the evidence remains limited. This information is derived only from authoritative scientific and regulatory sources and contains no clinical advice or statements about safety or dosing.

---

Evidence for Use in Short-Term Insomnia

Research for temazepam's use in insomnia—including difficulty falling asleep and staying asleep—primarily comes from short-term, placebo-controlled, randomized clinical trials (RCTs). These studies utilized specialized sleep laboratory settings to record objective sleep parameters, alongside patient-reported outcomes describing perceived discomfort. In these trials, research examined outcomes related to sleep maintenance, monitoring Total Sleep Time and the number of nighttime awakenings. Studies reported measurements showing patterns of change in total sleep time compared to the placebo control groups. However, when researchers examined the time required to fall asleep (sleep latency), the findings were mixed, and results varied across studies and measured parameters. Research provides context but does not determine whether an individual will respond similarly to the group patterns observed.

---

Long-Term Research and Follow-up Durations

The majority of evidence supporting the use of temazepam is derived from short-term observation periods, typically lasting 7 to 14 days, which reflects the design of the initial efficacy trials. Follow-up durations were limited across the core research base. Some research explored outcomes over an intermediate period, with a few controlled trials having observation periods that extended up to three months. Evidence for long-term use is limited. Studies conducted during periods of increased symptom activity focused on evaluating temporary changes in sleep parameters. Long-term effects are not fully established regarding sustained efficacy or the durability of the initial reported outcomes.

---

Research in Special Populations

Temazepam was evaluated in various populations to understand how the medication's effects were associated with different patient groups. Older adults (geriatric populations) were studied separately, recognizing that outcomes reflecting daily functioning or activity level may be different in this group. Studies have also monitored responses in specific subgroups, such as patients experiencing sleep disruption alongside advanced cancer. The results apply only to the populations studied, and data for certain groups remain insufficient.

---

Study Limitations and Unresolved Questions

The overall research landscape has several key limitations noted by researchers. Comparative evidence is lacking; for instance, there is limited information from studies comparing temazepam directly to non-pharmacological treatments (like cognitive behavioral therapy for insomnia) or newer drug classes. In addition to the limited long-term data, findings were mixed on certain outcomes, particularly regarding the consistency of measurements for sleep latency. Evidence quality varies across studies, and methodological quality contributes to areas of uncertainty where more research is ongoing.

Key Studies & References

1. Pharmacokinetics and clinical use of temazepam and related benzodiazepine hypnotics

Common questions about Restoril (FAQ)

Q: Is Restoril considered a narcotic?

Restoril (temazepam) is officially designated as a Schedule IV controlled substance by the U.S. Drug Enforcement Administration (DEA). This classification indicates that the drug has an accepted medical use and a potential for dependence. The term 'narcotic' is not the official classification used for temazepam; it is officially classified as a Schedule IV controlled substance.

Q: Why is Restoril only prescribed for short-term use?

Official product information indicates Restoril for the short-term treatment of insomnia, generally for a duration of 7 to 10 days. Prolonged use is generally limited due to the established risk of developing physical and psychological dependence on the medication. Abrupt cessation after extended use can also lead to the occurrence of withdrawal symptoms.

Q: How quickly does Restoril start working after I take it?

According to official pharmacokinetic studies, measurable levels of the drug in the bloodstream are typically seen within 10 to 20 minutes after a dose. Studies indicate that the medication typically reaches its peak concentration in the blood approximately 1.5 hours after administration.

Q: What is the typical half-life of Restoril (temazepam)?

The half-life of a drug refers to the time it takes for the amount of active substance in the body to be reduced by half. For temazepam, studies indicate that the half-life ranges from about 3.5 to 18.4 hours, with an average of approximately 8.8 hours in the studied populations.

Q: Are there any common foods that can interact with Restoril?

Official drug labels list a specific warning to avoid alcohol while using Restoril due to the risk of additive central nervous system (CNS) depressant effects. However, the regulatory documents do not specifically name common foods, such as particular fruit juices, as interacting with this medicine.

Q: Is Restoril used to treat anxiety or only insomnia?

Restoril is approved only for the short-term treatment of insomnia (sleep problems). Regulatory documents note that the drug is not intended for use alone to address depression or anxiety associated with depression.

Q: Are there any specific organs Restoril affects, like the liver or kidneys?

The drug is primarily processed in the liver before being eliminated from the body. Consequently, Restoril is contraindicated (must not be used) in patients who have severe hepatic (liver) insufficiency. While the medicine is processed in the liver, a specific contraindication related to kidney function is not cited in the official documents.

Q: Can Restoril interact with over-the-counter pain relievers?

Official labeling warns against taking Restoril with other Central Nervous System (CNS) depressants, which can cause excessive sedation and breathing problems. Official product information emphasizes the importance of discussing all over-the-counter medicines, including pain relievers, with a healthcare professional.

Q: Are there generic versions of Restoril available?

Yes, Restoril is the brand name for the active drug temazepam. The generic version, Temazepam Capsules, is also available on the market as described in official drug information sources.

Q: Can Restoril cause vivid dreams or nightmares?

Official lists of possible adverse reactions that affect the Central Nervous System include the possibility of increased dreaming. Patients who experience unusual sleep-related reactions may find it helpful to discuss them with a healthcare provider.

Q: How does the body eliminate Restoril after it is taken?

Temazepam is completely broken down (metabolized) through a process called conjugation, which occurs mainly in the liver. Following this process, between 80% and 90% of the dose is typically eliminated from the body through the urine.

Q: What are the signs of a possible allergic reaction to Restoril?

Severe allergic reactions, including a potentially fatal condition called anaphylaxis, are listed as serious side effects. The symptoms cited for a severe allergic reaction can include swelling of the tongue or throat, trouble breathing, and nausea and vomiting.

Q: What is the risk of overdose associated with Restoril?

Taking more than the prescribed amount of Restoril can lead to an overdose. The risk of serious outcomes like profound sedation, respiratory depression, coma, and death is significantly higher if Restoril is combined with opioids, alcohol, or other CNS depressants.

Q: Does Restoril interact with common supplements like melatonin or magnesium?

Official documents warn about combining Restoril with other medicines or substances that cause sleepiness or drowsiness. Regulatory documents emphasize that patients should inform their healthcare provider about all medicines, vitamins, and herbal supplements they are taking.

Q: How is Restoril different from other benzodiazepines used for sleep?

Temazepam is classified as an intermediate-acting benzodiazepine. This classification refers to the time the drug takes to be processed and eliminated by the body, offering a degree of distinction from very short- or very long-acting drugs in the same class.

Q: Does Restoril have a risk of misuse or abuse?

Yes, regulatory documents include a warning that temazepam is a federally controlled substance (C-IV) and carries a risk of abuse, misuse, and addiction. This risk is noted in the official Boxed Warning and reflects its classification as a sedative-hypnotic agent.

Q: What is meant by the term 'rebound insomnia' after stopping Restoril?

Rebound insomnia is a recognized risk associated with discontinuing the medication, particularly if stopped suddenly. It is described as a temporary return of sleep problems that may be worse than the insomnia that was initially treated. This is listed alongside other potential withdrawal symptoms.

Q: Can Restoril be taken if I am already taking an antidepressant?

Official labeling warns that Restoril should not be taken with other medicines that can cause sleepiness, which may include certain types of antidepressants. Official documents emphasize the importance of informing a healthcare provider about all current medications so a proper risk assessment can be made.

Q: Does Restoril interact with common cold or flu medications?

Restoril should not be taken with other Central Nervous System (CNS) depressants, and many cold and flu products contain such ingredients (like sedating antihistamines). Regulatory documents note that patients should inform their doctor about all prescription and non-prescription cold or flu medicines to manage the risk of combining CNS depressants.

Storage Requirements

Restoril (temazepam) must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The product must be kept away from excess heat and moisture and must not be frozen. Keep the medicine in its original, tightly closed container.

Security and Disposal

As a Schedule IV controlled substance, Restoril must be stored in a safe place and kept strictly out of the reach and sight of children. To dispose of unused or outdated medication, regulatory guidance advises using an official drug take-back program or consulting a healthcare professional for safe disposal instructions. Do not keep medicine that is no longer needed.